My name is Andrew Tobin.
I'm at the University of Glasgow at the Center for Translational pharmacology.
I'd like to present to you our work that we've been doing for,
I would say over the last 10 or 20 years,
looking at novel ways of treating
the symptoms and slowing the progression of neurodegenerative disease.
The structure of this lecture will be around a brief description of
dementia and current treatments that are
aimed really at symptomatic treatments for Alzheimer's disease.
Then, I'll be asking what are
the best disease models in which to study Alzheimer's disease,
and I'll be looking at our work using prion disease and asking
whether the prion disease mimics some of the hallmarks of Alzheimer's disease.
Then, I'm going into asking whether or not we can target
the M1 muscarinic acetylcholine receptors
to restore memory deficits in neurodegeneration.
A key feature, then, of the lecture will be to ask whether or
not we need to tailor the drugs,
particularly targeting the muscarinic receptor for
different stages of Alzheimer's disease,
where we might need different levels of modulation of disease.
Finally, bearing in mind
the adverse responses that many treatments have for Alzheimer's disease,
asking whether we can develop methods by which we can reduce adverse responses,
and therefore, have chronic treatment of disease that will
slow the progression of neurodegenerative disease.
So, that's the outline of the current lecture.